PDCD1 and dermatological toxicity: This prospective study clarified that the development of the specific irAEs (pituitary dysfunction, destructive thyroiditis, and skin toxicity) was associated with prolonged OS in NSCLC patients treated with anti-PD-1 antibodies even after accounting for ITB, suggesting that these irAEs could be prognostic biomarkers.